U.S. court orders Guardant to pay $245 million in DNA sequencing patent dispute

Guardant Health loses patent judgment; ordered to pay $245M

Guardant Health faces final patent judgment: $245M+ damages/royalties to TwinStrand/UW over Duplex Sequencing technology. Read more here.

Guardant Bleeds After Losing A Costly Patent Dispute

Guardant Health stock tumbled Monday after losing a patent battle against privately held TwinStrand Biosciences.

U.S. court orders Guardant to pay $245 million in DNA sequencing patent dispute

Aug 24 (Reuters) - A U.S. court has ordered Guardant Health to pay more than $245.2 million to TwinStrand Biosciences and the University of Washington ​after finding that the company infringed patents covering ‌DNA sequencing technology, TwinStrand sai...

TwinStrand Biosciences Announces Final Judgment in Patent Infringement Suit Against Guardant Health, Awarding TwinStrand and the University of Washington More Than $245.2 Million in Damages, Accrued Royalties and Interest

SEATTLE--(BUSINESS WIRE)--Aug 24, 2026-